Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Garcia-Torralba E, Garcia-Lorenzo E, Doger B, Spada F, Lamarca A. Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut. Cancers (Basel). 2024 Jul 13;16(14):2530. doi: 10.3390/cancers16142530. PubMed PMID: 39061170; PubMed Central PMCID: PMC11275146.
AÑO: 2024; IF: 4.4
39061170
Kwon M, Gomez-Centurion I, Oarbeascoa G, Torres M, Martinez AP, Suarez-Lledo M, Chinea A, Cascon MJP, Vazquez L, Espigado I, Izquierdo I, Parody R, Cadenas IG, Calbacho M, Sierra PG, Heras I, Yanez L, Torrent A, Bautista G, Gonzalez S, Roldan E, Vallejo JC, Bailen R, Borrero A, Lopez-Jimenez J, Casas MAC, Solano C; Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC). Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain. Transplant Cell Ther. 2024 Oct;30(10):1033.e1-1033.e8. doi: 10.1016/j.jtct.2024.06.009. Epub 2024 Jun 12. PubMed PMID: 38871055.
AÑO: 2024; IF: 4.4
38871055
Borsellino B, Bravo-Perez C, Visconte V, Guarnera L. Thrombosis in Myeloid Malignancies: From CHIP to AML. Cardiovasc Hematol Disord Drug Targets. 2024;24(1):2-12. doi: 10.2174/011871529X307253240530060107. PubMed PMID: 38879768.
AÑO: 2024
38879768
Rey-Bua B, Grande C, Sanchez Blanco JJ, Abrisqueta P, Gutierrez A, Ramirez Payer A, Gine E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Penarrubia MJ, Jimenez-Ubieto A, Montes-Moreno S, Lopez-Guillermo A, Caballero MD, Martin Garcia-Sancho A. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. PubMed PMID: 38900037.
AÑO: 2024; IF: 10.2
38900037
Suarez EU, Boluda B, Lavilla E, Tormo M, Botella C, Gil C, Vives S, Rodriguez C, Serrano J, Sayas MJ, Martinez-Sanchez P, Ramos F, Bernal T, Algarra L, Bergua-Burgues JM, Perez-Simon JA, Herrera P, Barrios M, Noriega-Concepcion V, Raposo-Puglia JA, Ayala R, Barragan E, Martinez-Cuadron D, Amigo ML, Lopez-Lorenzo JL, Lazaro-Garcia A, Guimaraes JE, Colorado M, Garcia-Boyero R, De Rueda-Ciller B, Foncillas-Garcia M, Hong A, Labrador J, Alonso-Dominguez JM, Montesinos P; PETHEMA group. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens? Ann Hematol. 2024 Aug;103(8):2845-2851. doi: 10.1007/s00277-024-05840-7. Epub 2024 Jun 17. PubMed PMID: 38884787.
AÑO: 2024; IF: 2.4
38884787
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL